April 2, 2018 10:34 AM EDT

AstraZeneca hands Compugen $10M to launch I/O discovery deal; RA Capital joins opposition to proposed BioCryst/Idera merger

John Carroll

Editor & Founder

→ Israel’s Compugen $CGEN nabbed a $10 million upfront to get started on a discovery deal with AstraZeneca on bi- and multi-specific antibodies for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca hands Compugen $10M to launch I/O discovery deal; RA Capital joins opposition to proposed BioCryst/Idera merger

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

As­traZeneca hands Com­pu­gen $10M to launch I/O dis­cov­ery deal; RA Cap­i­tal joins op­po­si­tion to pro­posed BioCryst/Idera merg­er

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

AstraZeneca hands Compugen $10M to launch I/O discovery deal; RA Capital joins opposition to proposed BioCryst/Idera merger